Drug Discovery

The persistent reliance on a trial-and-error method for prescribing pharmaceutical treatments continues to result in significant healthcare inefficiencies and preventable patient suffering throughout the United States. Twinsburg-based Xact Laboratories has addressed this critical gap by securing a

The strategic deployment of the ADME-One™ platform represents a fundamental restructuring of the traditional pharmaceutical pipeline, which has long been haunted by the notorious "valley of death" where promising chemical leads frequently vanish during clinical trials due to unforeseen metabolic

The ability to peer into the biological future of a patient by predicting how a radioactive drug will distribute through their unique anatomy represents a monumental leap in the fight against advanced prostate cancer. The field of oncology is currently navigating a fundamental shift where treatment

The persistent challenge of treating non-small cell lung cancer lies not in the absence of potent therapeutic agents but in the inherent difficulty of delivering these treatments exclusively to malignant cells while preserving the integrity of surrounding healthy pulmonary tissue. Modern oncology

Patients diagnosed with metastatic colorectal cancer carrying the BRAF V600E mutation have long navigated a clinical landscape where conventional chemotherapy often fails to provide lasting control over their disease. This specific genetic signature, found in approximately ten percent of metastatic

The pharmaceutical industry has long grappled with the high failure rates of clinical trials that often stem from a fundamental lack of understanding regarding the intricate spatial relationships within human tissues. While genomic and transcriptomic profiling provided a foundational blueprint for